Diamyd Medical AB (publ)

Stockholm Stock Exchange DMYD-B.ST

Diamyd Medical AB (publ) Cash and Short-Term Investments for the year ending August 31, 2024

Diamyd Medical AB (publ) Cash and Short-Term Investments is NA for the year ending August 31, 2024. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

Diamyd Medical AB (publ) Cash and Short-Term Investments for the year ending August 31, 2023 was USD 11.59 M, a -22.26% change year over year.
Diamyd Medical AB (publ) Cash and Short-Term Investments for the year ending August 31, 2022 was USD 14.91 M, a -7.36% change year over year.
Diamyd Medical AB (publ) Cash and Short-Term Investments for the year ending August 31, 2021 was USD 16.10 M, a 104.23% change year over year.
Diamyd Medical AB (publ) Cash and Short-Term Investments for the year ending August 31, 2020 was USD 7.88 M.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

Stockholm Stock Exchange: DMYD-B.ST

Diamyd Medical AB (publ)

CEO	Mr. Ulf Hannelius MBA, Ph.D.
IPO Date	May 20, 2013
Location	Sweden
Headquarters	Kungsgatan 29
Employees	27
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals Vaccines

Description

Diamyd Medical AB (publ) develops therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy diabetes vaccine, which is in phase IIb clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes; and Remygen, an oral regenerative and immunomodulatory drug candidate, which is in phase I/II clinical trial for the treatment of autoimmune and type 2 diabetes. The company was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB (publ) in April 2013. Diamyd Medical AB (publ) was incorporated in 1984 and is based in Stockholm, Sweden.

Key trends

Past 5 years